Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

<p>Table S8. Genes used for gene set analysis</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Sung-Eun Lee (14855067) (author)
Diğer Yazarlar:	Feng Wang (14855070) (author), Maison Grefe (14855073) (author), Abel Trujillo-Ocampo (14855076) (author), Wilfredo Ruiz-Vasquez (14855079) (author), Koichi Takahashi (14855082) (author), Hussein A. Abbas (14855085) (author), Pamella Borges (14855088) (author), Dinler Amaral Antunes (14855091) (author), Gheath Al-Atrash (14855094) (author), Naval Daver (14855097) (author), Jeffrey J. Molldrem (14855100) (author), Andrew Futreal (14855103) (author), Guillermo Garcia-Manero (14855106) (author), Jin S. Im (14855109) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Immuno-oncology Hematological Cancers Immunotherapy Checkpoint blockade Tumor Microenvironment Tumor microcirculation
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Table S2 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
Yazar:: Dong-Chun Hong (16374308)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
Yazar:: Yibin Dai (16374331)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
Yazar:: Yibin Dai (16374331)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Yazar:: Alessio Cortellini (11023993)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Yazar:: Christine Pich-Bavastro (16509238)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Yazar:: Alessio Cortellini (11023993)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Yazar:: Alessio Cortellini (11023993)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Yazar:: Alessio Cortellini (11023993)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Yazar:: Alessio Cortellini (11023993)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Yazar:: Alessio Cortellini (11023993)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Yazar:: Alessio Cortellini (11023993)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Yazar:: Alessio Cortellini (11023993)
Baskı/Yayın Bilgisi: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
Yazar:: Xiaodong Shu (16721586)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
Yazar:: Xiaodong Shu (16721586)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
Yazar:: Xiaodong Shu (16721586)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
Yazar:: Xiaodong Shu (16721586)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
Yazar:: Xiaodong Shu (16721586)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
Yazar:: Xiaodong Shu (16721586)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
Yazar:: Xiaodong Shu (16721586)
Baskı/Yayın Bilgisi: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
Yazar:: Xiaodong Shu (16721586)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
Yazar:: Arianna Draghi (15126339)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
Yazar:: Clare Vesely (505402)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_v9kcjipvc9d2rrqosf89ilr6a7